ArticleScience advances2017
Comprehensive vaccine design for commensal disease progression.
Article in Science advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Glycoconjugate vaccines: platforms and adjuvants for directed immunity.Glycobiology · 2024Review
- Harnessing synthetic biology for advancing RNA therapeutics and vaccine design.NPJ systems biology and applications · 2023Review
- Influence of glycan structure on the colonization ofProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Recent advances on smart glycoconjugate vaccines in infections and cancer.The FEBS journal · 2022Review
- Prophylactic vaccine delivery systems against epidemic infectious diseases.Advanced drug delivery reviews · 2021Review
- Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease.Vaccines · 2021Review
- Liposomal Encapsulation of Polysaccharides (LEPS) as an Effective Vaccine Strategy to Protect Aged Hosts AgainstFrontiers in aging · 2021Article
- Extended Polysaccharide Analysis within the Liposomal Encapsulation of Polysaccharides System.Materials (Basel, Switzerland) · 2020Article
- Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System.Materials (Basel, Switzerland) · 2019Article
- Antigen delivery format variation and formulation stability through use of a hybrid vector.Vaccine: X · 2019Article
- Engineering a Next-Generation Glycoconjugate-Like Streptococcus pneumoniae Vaccine.ACS infectious diseases · 2018Article
- Standardization of Pneumococcal Biofilm Release to PncO Expression, a Predictive Measurement of Virulence.Infection and immunity · 2018Article
- Phenotypic Variation during Biofilm Formation: Implications for Anti-Biofilm Therapeutic Design.Materials (Basel, Switzerland) · 2018Review
- Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends.Molecules (Basel, Switzerland) · 2018Review
- Potential targets for next generation antimicrobial glycoconjugate vaccines.FEMS microbiology reviews · 2018Review
- Human Vaccines & Immunotherapeutics: News.Human vaccines & immunotherapeutics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Commensal organisms with the potential to cause disease pose a challenge in developing treatment options. Using the example featured in this study, pneumococcal disease begins with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.